I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Revenue of I-Mab (IMAB)
Revenue in 2023 (TTM): $27.64 M
According to I-Mab's latest financial reports the company's current revenue (TTM) is $27.64 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of I-Mab
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $27.64 M | $27.64 M | $-1,212,070,000 | $-1,465,694,000 | $-1,465,694,000 |
| 2022 | $-221,563,000 | $-248,800,000 | $-1,944,127,000 | $-2,506,620,000 | $-2,507,317,000 |
| 2021 | $88.03 M | $41.59 M | $-2,057,531,000 | $-2,334,695,000 | $-2,331,541,000 |
| 2020 | $1.54 B | $1.54 B | $168.31 M | $483.15 M | $470.92 M |
| 2019 | $30 M | $30 M | $-1,455,137,000 | $-1,451,950,000 | $-1,485,001,000 |
| 2018 | $53.78 M | $53.78 M | $-431,898,000 | $-401,111,000 | $-402,833,000 |
| 2017 | $11.56 M | $11.56 M | $-279,321,000 | $-298,240,000 | $-298,240,000 |